Details of the Drug Reposition

General Information of This Drug (ID: DMPDA17)

Drug Name
Omburtamab I-131   DMPDA17

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroblastoma DISVZBI4 2D11.2 Phase 2/3 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Small round cell desmoplastic tumour DISSLUVI 2A20.5 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03275402) 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)